Literature DB >> 11328586

Activation by 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, of p42/44 mitogen-activated protein kinase in HL-60 cells.

Y Kobayashi1, S Arai, K Waku, T Sugiura.   

Abstract

2-Arachidonoylglycerol (2-AG), an endogenous cannabinoid receptor ligand, was shown to induce rapid phosphorylation of p42/44 mitogen-activated protein kinase (MAP kinase) in HL-60 cells. We confirmed that the enzyme activity of p42/44 MAP kinase in HL-60 cells was augmented markedly when the cells were stimulated with 2-AG. The addition of SR144528, a cannabinoid CB2 receptor-specific antagonist, to the cells prior to the addition of 2-AG abolished the response induced by 2-AG, indicating that the CB2 receptor is involved in the response. G protein G(i) or G(o) is also assumed to be involved, because pertussis toxin treatment of the cells nullified the response induced by 2-AG. CP55940 and anandamide also induced the activation of p42/44 MAP kinase, although the activation by anandamide was less pronounced than that by 2-AG or CP55940. These results suggest that 2-AG may play an important physiological role in this type of cell through the activation of the p42/44 MAP kinase cascade.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328586     DOI: 10.1093/oxfordjournals.jbchem.a002904

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  11 in total

Review 1.  Endocannabinoids and immune regulation.

Authors:  Rupal Pandey; Khalida Mousawy; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Pharmacol Res       Date:  2009-04-07       Impact factor: 7.658

Review 2.  Cannabinoid control of neurogenic inflammation.

Authors:  Meagan McKenna; Jason J McDougall
Journal:  Br J Pharmacol       Date:  2020-08-13       Impact factor: 8.739

3.  Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies.

Authors:  Sabine Steffens; Pál Pacher
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells.

Authors:  Maiko Gokoh; Seishi Kishimoto; Saori Oka; Masahiro Mori; Keizo Waku; Yoshio Ishima; Takayuki Sugiura
Journal:  Biochem J       Date:  2005-03-15       Impact factor: 3.857

Review 5.  What we know and do not know about the cannabinoid receptor 2 (CB2).

Authors:  Anna Maria Malfitano; Sreemanti Basu; Katarzyna Maresz; Maurizio Bifulco; Bonnie N Dittel
Journal:  Semin Immunol       Date:  2014-05-28       Impact factor: 11.130

6.  Endocannabinoid hydrolases in avian HD11 macrophages identified by chemoproteomics: inactivation by small-molecule inhibitors and pathogen-induced downregulation of their activity.

Authors:  Jung Hwa Lee; Xiang Hou; Evangel Kummari; Abdolsamad Borazjani; Mariola J Edelmann; Matthew K Ross
Journal:  Mol Cell Biochem       Date:  2017-12-01       Impact factor: 3.396

7.  GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current.

Authors:  Jane E Lauckner; Jill B Jensen; Huei-Ying Chen; Hui-Chen Lu; Bertil Hille; Ken Mackie
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-08       Impact factor: 11.205

8.  Cannabinoid CB2 receptors contribute to upregulation of β-endorphin in inflamed skin tissues by electroacupuncture.

Authors:  Tang-feng Su; Ling-hong Zhang; Miao Peng; Cai-hua Wu; Wen Pan; Bo Tian; Jing Shi; Hui-lin Pan; Man Li
Journal:  Mol Pain       Date:  2011-12-19       Impact factor: 3.395

Review 9.  The CB2 receptor and its role as a regulator of inflammation.

Authors:  Caroline Turcotte; Marie-Renée Blanchet; Michel Laviolette; Nicolas Flamand
Journal:  Cell Mol Life Sci       Date:  2016-07-11       Impact factor: 9.261

10.  The second intracellular loop of the human cannabinoid CB2 receptor governs G protein coupling in coordination with the carboxyl terminal domain.

Authors:  Congxia Zheng; Linjie Chen; Xiaopan Chen; Xiaobai He; Jingwen Yang; Ying Shi; Naiming Zhou
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.